You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Caspase-3 inhibitor Z-DEVD-FMK enhances retinal ganglion cell survival and vision restoration after rabbit traumatic optic nerve injury

Article type: Research Article

Authors: Liu, Yuanyuan | Yan, Hua | Chen, Song | Sabel, Bernhard A.

Affiliations: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China | Institute of Medical Psychology, Medical Faculty, Otto.-v.-Guericke University of Magdeburg, Magdeburg, Germany

Note: [] Corresponding author: Dr. Hua Yan, Department of Ophthalmology, Tianjin Medical University General Hospital, No. 154, Anshan Road, Tianjin 300052, China. Tel.: +86 22 60362465; Fax: +86 22 27813550; E-mail: [email protected]

Note: [] Song CHEN is co-first author.

Keywords: Caspase-3 inhibitor, optic nerve injury, apoptosis, neuroprotection, vision restoration

DOI: 10.3233/RNN-159001

Journal: Restorative Neurology and Neuroscience, vol. 33, no. 2, pp. 205-220, 2015

Published: 2015
Get PDF

Abstract

Purpose: Vision loss after traumatic optic nerve injury is considered irreversible because of the retrograde loss of retinal ganglion cells (RGCs) which undergo apoptosis. Because the second messenger caspase-3 plays a major role in apoptosis, we now evaluated the efficacy of the specific caspase-3 inhibitor, Z-DEVD-FMK, in a rabbit model of fluid percussion injury (FPI) which mimics traumatic optic nerve injury in humans to enhance cell survival and improve vision. Methods: Survival of RGCs and recovery of vision were studied using retinal morphological markers and visual evoked potentials (VEP), respectively. The FPI traumatized animals were treated in their right eye with a single intravitreal or peribulbar injection of Z-DEVD-FMK 30 min post-injury compared to 2% DMSO control injections in their left eye. Results: Intravitreal Z-DEVD-FMK, but not control injections, led to down-regulation of capase-3 and reduced, in a dose-dependent manner, RGCs apoptosis from 7 to 21 days post-injury. These morphological improvements were accompanied by vision restoration as documented by VEP. The neuroprotection after intravitreal injection of Z-DEVD-FMK was more effective than the peribulbar application. Conclusions: The caspase-3 inhibitor Z-DEVD-FMK is neuroprotective by inhibiting RGCs apoptosis when injected 30 min after optic nerve damage and significantly promotes restoration of vision. A controlled clinical trial is now needed to evaluate the efficacy and safety of Z-DEVD-FMK in humans.

Show more